New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT05227326
Summary
This is the first human study of an experimental oral drug called AOH1996 for patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand how the body processes the drug. Researchers will enroll about 92 adults with various cancers including ovarian, lung, pancreatic, and certain sarcomas to test if the drug can slow tumor growth by blocking enzymes cancer cells need.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Honor Health Research and Innovation Institute
NOT_YET_RECRUITINGScottsdale, Arizona, 85258, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.